Delta 4
Main Menu
Main Menu

Author: Kurt Herpel

CEO of Delta4

Delta4’s Year in Review: Strong Momentum in 2025 Fuels Ambitious Plans for 2026

Three men sit at a table having a discussion; one has a laptop open, and documents and pens are on the table.

As 2025 draws to a close, Delta4 reflects on a remarkable year of scientific achievement, strategic partnerships, and technological advancement. From securing national recognition to publishing cutting-edge research and advancing major EU initiatives, Delta4 has demonstrated that AI-powered drug discovery, grounded in rigorous computational biology, is not only possible but scalable and impactful. “2025 has […]

Long COVID: Symptoms, Causes, and How AI Is Ushering New Hope

Person wearing blue gloves and a lab coat typing on a laptop in a laboratory setting.

Long COVID is a chronic state that can be diagnosed when symptoms or diagnosable conditions persist for at least three months following a SARS-CoV-2 infection. It falls under a broader category known as post-acute sequelae of SARS-CoV-2 infection (PASC) and is recognized as a newly emerging infection-associated chronic condition (IACC). What makes Long COVID particularly […]

Delta4 Advances Kidney Health with ADPKD Research & Partnerships

Medical illustration of the human torso highlighting the kidneys and urinary tract in orange, emphasizing their position within the body and underscoring the importance of kidney health.

We are excited to share several important milestones that reflect our ongoing commitment to kidney health: advancing a new research collaboration with the Medical University of Innsbruck supported by the FFG Austrian Research Promotion Agency, joining the Signals Directory (Kidneyverse), and highlighting a valuable toolkit from the International Society of Nephrology (ISN) to raise awareness […]

Delta4 At PICKED

Delta4 logo with text "EU-Funded PhD Program in Kidney Disease Research" next to an illustrated human torso highlighting the kidneys, picked to showcase innovative research opportunities.

Teaming Up for Better CKD Care: Delta4 at the PICKED & DisCo-I Meeting in Toulouse | May 13-15, 2025 From May 13–15, 2025, Delta4’s Computational Biology Lead, Paul Perco, and Enrico Bono, MSCA-PICKED PhD Student, joined a dynamic mix of researchers, clinicians, and MSCA fellows in sunny Toulouse for a joint meeting of the PICKED […]

Delta4 Leads Training on Big Data Applications in CKD Research at PerMediK Lisbon, March 2025

Delta team

Continuing its active engagement with the COST Action PerMediK network, Delta4 participated in the 6th Management Committee Meeting and Action Workshop held in Lisbon, Portugal on March 14–15, 2025. Representing Delta4, Lead Software Engineer Matthias Ley led the opening training session titled “Leveraging Big Data for Chronic Kidney Disease Research: Real-World Use-Cases and Data Skills […]

Delta4 Secures European Patents for Two Compounds as Candidate Treatments for Focal Segmental Glomerulosclerosis (FSGS)

A person in a lab coat and gloves types on a keyboard, their actions illuminated by the glow of a computer screen displaying data. As they work, Delta4 secures European patents in the background, symbolizing innovation and meticulous research at its finest.

Vienna, Austria – January 31th, 2025 – Delta4, a leader in AI-driven drug discovery and indication expansion, is proud to announce that it has been granted European patents for two innovative compounds positioned as candidate treatments for focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disease. These patents mark a significant milestone in Delta4’s […]

Delta4 Featured on PharmaVentures Podcast: AI in Drug Discovery

Scientist in a lab coat uses a computer displaying DNA analysis, with test tubes and a microscope nearby.

Delta4’s CEO, Kurt Herpel, and CSO, Klaus Kratochwill, were recently featured on the PharmaVentures podcast, where they discussed how Delta4 is transforming the landscape of drug discovery through AI. This engaging conversation sheds light on the roots of the company and the innovative work happening at Delta4, as well as the potential of AI to […]

Delta4: A Trusted Partner in EU Horizon Research Projects

A woman in a lab coat and glasses works on a laptop in a dimly lit room with multiple screens displaying data in the background, as part of the EU Horizon Research initiative. Other individuals also work at computers behind her, contributing to the collaborative effort.

Delta4 is proud to announce its participation in two significant EU Horizon research projects: PICKED (Personalized Medicine in Chronic Kidney Disease) and PROMOTE (Prostate Cancer Omics Mediated Intervention). Horizon Europe is the world’s largest research funding program, focusing on advancing health, biomedical research, data science, and AI/ML. With a total budget of nearly EUR 100 […]

Delta4 Featured in the Finanz und Wirtschaft (FuW)

A scientist works on a computer displaying medical data. In the background, two other scientists conduct experiments in a lab. The environment is bright and clinical.

Delta4 is honored to have been featured in a recent article by Finanz und Wirtschaft, highlighting our pioneering work in AI-driven drug repurposing. The article sheds light on how our AI-powered platform, Hyper-C, identifies novel therapeutic uses for existing drugs, offering hope for more efficient and effective treatment strategies for a range of complex conditions. […]

The Path to New Therapies for Focal Segmental Glomerulosclerosis (FSGS)

Hands holding a paper cutout of a red kidney on a light blue background.

Developing new treatments for complex diseases presents a myriad of challenges, ranging from understanding the disease’s mechanisms to ensuring the safety and effectiveness of proposed therapies. At Delta4, we’re passionately pursuing new treatments for Focal Segmental Glomerulosclerosis (FSGS). Leveraging our in-silico platform, Hyper-C, we’ve been able to identify new potential therapeutic options for FSGS. This […]